A5015708727- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Extracellular vesicles in disease
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Cancer-related Molecular Pathways
- Ferroptosis and cancer prognosis
- MicroRNA in disease regulation
- Circular RNAs in diseases
- Cancer Immunotherapy and Biomarkers
- Cancer Mechanisms and Therapy
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- Lung Cancer Research Studies
- Cancer, Lipids, and Metabolism
- Cancer-related molecular mechanisms research
- RNA modifications and cancer
- Chromatin Remodeling and Cancer
- Cancer, Hypoxia, and Metabolism
- Lung Cancer Treatments and Mutations
- Epigenetics and DNA Methylation
- DNA Repair Mechanisms
- Nanoparticle-Based Drug Delivery
- Sesquiterpenes and Asteraceae Studies
Fudan University Shanghai Cancer Center
2016-2025
Shanghai Medical College of Fudan University
2015-2025
State Key Laboratory of Genetic Engineering
2024
Southwest Medical University
2013-2021
Tennessee Oncology
2016
Fudan University
2011-2015
First Affiliated Hospital of Sichuan Medical University
2013
Zhongshan Hospital
2011-2013
Ministry of Education of the People's Republic of China
2013
Cancer-associated fibroblasts (CAFs) are abundant stromal cells in the tumor microenvironment that promote cancer progression and relapse. However, heterogeneity regulatory roles of CAFs underlying chemoresistance remain largely unclear. Here, we performed a single-cell analysis using high-dimensional flow cytometry identified distinct senescence-like tetraspanin-8 (TSPAN8)
Analysis of extracellular vesicles (EV) is a promising noninvasive liquid biopsy approach for breast cancer detection, prognosis, and therapeutic monitoring. A comprehensive understanding the characteristics proteomic composition cancer-specific EVs from human samples required to realize potential this strategy. In study, we applied mass spectrometry-based, data-independent acquisition characterize serum derived patients with (n = 126) healthy donors 70) in discovery cohort validated...
Background: Ferroptosis plays a vital role in cancer development and treatment. The relationship between ferroptosis-related genes breast prognosis, as well immunotherapy outcomes, remains unknown. Objectives: To evaluate the prognostic value of cancer. Methods: We conducted differential expressions analysis for on public databases patients our center analyzed their predictive patients. Results: identified genes, constructed nomogram, validated key using patient data from center. also...
Abstract BACKGROUND: PIWI protein family was found to play an important role in stem cell self‐renewal. Overexpression of HIWI, the human homolog proteins, several solid tumors, although HIWI hepatocellular carcinoma (HCC) and its prognostic value remain unclear. METHODS: expression measured stepwise metastatic HCC lines (HCCLM3, MHCC97H, MHCC97L, SMMC7721, HepG2), normal liver line (L02), tissue samples (n = 20). Proliferation invasion were investigated undergoing target small interfering...
BackgroundCBCSG006 trial reported the superior efficacy of cisplatin plus gemcitabine (GP) regimen than paclitaxel (GT) as first-line treatment metastatic triple-negative breast cancer (mTNBC). This study focused on updated survival data and explorations potential biomarkers for efficacy.Patients methodsGerm-line mutations homologous recombination (HR) panel, BRCA1/2 included, were evaluated in 55.9% (132/236) patients. PD-L1 expression was 48.3% (114/236) A nonparametric sliding-window...
Abstract Exosomes are carriers of intercellular information that regulate the tumor microenvironment, and they have an essential role in drug resistance through various mechanisms such as transporting RNA molecules proteins. Nevertheless, their effects on gemcitabine triple-negative breast cancer (TNBC) unclear. In present study, we examined exosomes TNBC cell viability, colony formation, apoptosis, annexin A6 (ANXA6)/EGFR expression. We addressed roles underlying mechanism. Our results...
// Yannan Zhao 1, * , Chengcheng Gong Zhonghua Wang 1 Jian Zhang Leiping Sheng Jun Cao Tao Ting Li Biyun and Xichun Hu Department of Medical Oncology, Fudan University Shanghai Cancer Center, College, University, 200032, China These authors have contributed equally to this work Correspondence to: Wang, email: wangbiyun0107@hotmail.com Hu, xchu2009@hotmail.com Keywords: metastatic breast cancer, hormone receptor positive, endocrine therapy, metformin, pre-treated Received: April 18, 2017...
Abstract Background Novel human epidermal growth factor receptor 2 (HER2)-directed antibody–drug conjugates prompt the identification of HER2-low subtype. However, biological significance expression in breast cancer is unclear. Methods Clinical and genomic data 579 metastatic patients were reviewed from our next-generation sequencing (NGS) database analysis early TCGA was also analyzed. Findings First, clinicopathological characteristics profoundly influenced by HR status no difference...
In non-small-cell lung carcinoma (NSCLC) patients, the L858R/T790M mutation of epithelial growth factor receptor (EGFR) is a major cause acquired resistance to EGFR-TKIs treatment that limits their therapeutic efficacy. Identification drugs can preferentially kill NSCLC harbouring therefore critical. Here, we have evaluated effects ursolic acid, an active component isolated from herbal sources, on erlotinib-resistant H1975 cells harbour mutation.Gene expression omnibus (GEO) profiles...
Pyrotinib is a newly-developed irreversible pan-ErbB receptor tyrosine kinase inhibitor. This study reported the first real-world data of pyrotinib-based therapy in metastatic human epidermal growth factor 2 (HER2)-positive breast cancer (BC), focusing on efficacy lapatinib-treated patients and brain metastasis.One hundred thirteen with HER2-positive BC treated Fudan University Shanghai Cancer Center under non-clinical trial settings from September 1, 2018 to March 2019 were included.Over...
bHLH/PAS proteins play important roles in tumor progression. Lost or reduced expression of single-minded homolog 2 (SIM) as well aryl hydrocarbon receptor repressor (AHRR) has been observed cancerous human tissues. Here, we investigated the role nuclear translocator (ARNT), another protein, hepatocellular carcinoma (HCC). Using tissue microarray and immunohistochemistry, found that intratumoral ARNT was inversely correlated with time to recurrence overall survival HCC patients after...
The results of recent studies investigating the role platinum-based chemotherapy (PBCT) in metastatic triple-negative breast cancer (mTNBC) were conflicting. We retrospectively investigated a large cohort (n = 379) mTNBC to re-evaluate platinums. Longer PFS was found patients with PBCT than those non-PBCT (7.8 vs. 4.9 months, P < 0.001) as first-line chemotherapy, but no statistical difference OS observed. Compared other kinds platinum, cisplatin-based regimens showed better (8.0 4.3 0.03)...
Purpose Gemcitabine-based chemotherapy remains one of the standards in management metastatic breast cancer. However, intrinsic and acquired resistance to gemcitabine inevitably occurs. The aims this study were assess efficacy combination src inhibition gemcitabine-resistant cancer cells. Methods Results By using colony formation, sphere forming, flow cytometry, cell counting kit-8 transwell assays, 231/GEM-res (gemcitabine-resistant) line, which was 10 times more resistant, shown have...
Purpose: Triple-negative breast cancer is characterized by fast progression with high possible for metastasis and poor survival. Dysfunction of microRNAs plays an important role in the initiation cancer. Our previous microRNA-seq data indicated downregulation miR-331-3p triple-negative tissues compared that noncancer tissues. However, function remains largely unknown. Herein, involvement was investigated therapeutic potential also explored. Methods: Real-time quantitative polymerase chain...
Hypopharyngeal squamous-cell carcinoma (HSCC) is a relatively rare head and neck cancer, with great variation in patient outcomes. This study aimed to develop prognostic nomogram for patients HSCC. From the Surveillance, Epidemiology, End Results (SEER) database, we retrieved clinical data of 2198 diagnosed HSCC between 2010 2016. The were randomly assigned at 4:1 ratio training set or validation set. An external was performed by 233 locally advanced treated our center. A Cox proportional...
The LORDSHIPS study aimed to explore the safety and efficacy of a novel fully oral triplet combination dalpiciclib (a potent cyclin-dependent kinase 4/6 inhibitor), pyrotinib HER2 tyrosine inhibitor) endocrine therapy letrozole in patients with HER2-positive, hormone receptor (HR)-positive metastatic breast cancer (MBC) front-line setting.Postmenopausal women HR-positive MBC were recruited dose-finding phase Ib trial. A standard 3 + design was used determine safety, tolerability, recommended...
To evaluate the feasibility of early metabolic change assessed by PET in predicting clinical response to chemotherapy and investigate its prognostic value patients with advanced gastric cancer.A total 64 cancer were prospectively enrolled examined (18)F-fluorodeoxyglucose (FDG) (18)F-fluoro-3'-deoxy-3'-L-fluorothymidine (FLT) at baseline 14 days after treatment initiation. findings analyzed for correlation best patients, disease control status, survival identifying threshold percentage ROC...
Background: Breast cancer (BC) is a type of disease with high heterogeneity. Molecular profiling, by revealing the intrinsic nature its various subtypes, has extensively improved therapeutic management BC patients. However, genomic mutation landscape Chinese metastatic not been fully explored. Methods: Matched plasma and mononuclear cells from 290 women were sequenced using either two commercially-available panels consisting 520 cancer-related 108 BC-related genes. Both cover same critical...
Summary Purpose. This trial aimed to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection (Lipo-MIT) in advanced breast cancer (ABC). Methods. In this randomized, open-label, active-controlled, single-center, phase II clinical trial, eligible patients were randomized a ratio 1:1 receive Lipo-MIT or (MIT) intravenously. The primary endpoint was objective response rate (ORR). secondary endpoints disease control (DCR), progression-free survival (PFS), outcomes....
Background: Platinum-based regimens are the mainstay treatments for advanced triple-negative breast cancer (TNBC). Preclinical studies have shown that histone deacetylase (HDAC) inhibitor chidamide induced antitumor effects in TNBC, and plus chemotherapy was to be tolerable several malignancies. This study sought investigate efficacy safety of a combination treatment cisplatin metastatic TNBC patients. Methods: In this phase II, single-arm study, women with were administered (20 mg twice...